You are here

News

April

Hearing Loss Association of America
Apr 2014   The Hearing Loss Association of America® (HLAA) is the nation's foremost membership and advocacy organization for people with hearing loss. The mission of HLAA is to open the world of communication for people with hearing loss through information, education, support and advocacy.
Roberto Waddington
Apr 2014   This simple question has been lingering unanswered over private cord blood banks around the world for years. Despite compelling data on the growing therapeutic use of cord blood, both in terms of treatable diseases and numbers of therapies, often medical doctors are still reluctant to embrace the value of family cord blood banking. In many countries, such as Brazil, this sector is still plagued with mostly unfounded controversy, such as the "public versus private" banking debate.

March

Morey Kraus
Mar 2014   Babies born prematurely often have serious medical complications that impact their lungs, brain, kidneys and intestinal systems. Stem cells in the umbilical cord blood and tissue, collected after the baby is born, may offer new treatment options for these premature babies. In an effort to understand the potential for the babies' newborn stem cells to be used in such treatments, ViaCord established a pilot program in partnership with Miracle Babies charity and Sharp Mary Birch Hospital in San Diego.
Borne - Chelsea and Westminster Health Charity
Mar 2014   Borne's goal is to make childbirth safer and promote lifelong health for mothers and babies. Borne was set up in response to a need for greater research into the risks of premature birth. In the UK, more than 1 in 10 babies are born too soon. Worldwide, 15 million babies are born prematurely every year, and this is responsible for 70% of disability and death in newborn babies.
Mar 2014   Each year in the US, nearly 500,000 babies are born premature. That's 1 of every 8 infants born in the United States. A premature birth is when a baby is born before 37 completed weeks of pregnancy. A full-term pregnancy is 40 weeks. In almost all countries with reliable data, preterm birth rates are increasing.

February

CureCP
Feb 2014   There is growing acceptance in the medical community that stem cells derived from cord blood have value as a therapy for pediatric neurologic injury. But what financial hurdles do parents face when they attempt to access that value for their children? In this article we present a case study of the out-of-pocket costs that parents face when they use their child's own (autologous) cord blood as therapy for cerebral palsy, and receive the treatment at Duke University Medical Center ("Duke" hereafter).
Frances Verter, PhD (photo by Cate Rainbow)
Feb 2014   There should be thousands of children worldwide who already have a cerebral palsy diagnosis and have their own cord blood in storage, based on the epidemiology of the disorder and the inventory of cord blood in family banks. If autologous cord blood therapy for cerebral palsy is accepted as a standard of care, those children are the immediate potential market for therapy. If therapy with matched cord blood donations is also accepted, even more children will potentially have access, but the cost of therapy will go up dramatically, and the search for a matching cord blood unit will complicate their ability to access this therapy.

January

authors Anzalone and La Rocca
Jan 2014   When someone thinks to the potential of regenerative medicine, the main idea is that of immature cells which may transdifferentiate towards a mature cell type, which may be used to repopulate a target organ cells, and thereby treat human diseases. This concept drives a lot of research undertaken worldwide. Wharton's jelly mesenchymal stem cells (WJ-MSC) are not an exception to this rule: They are derived from the tissue constituting the bulk of the umbilical cord (1). Applications of these cells, often supported by data from several in vivo models, range from the nervous system to the liver, pancreas, heart and other organs in the body (2-4).
Jan 2014   Recently, two exciting studies in China were published that highlight the co-transplantation of human umbilical cord mesenchymal stem cells (UC-MSC) and human umbilical cord blood hematopoietic stem cells (CB-HSC) into human patients. These papers provide some of the first human data to support a scientific hypothesis that was first suggested at the 7th International Cord Blood Society (ICBS) Congress in 2004 (1).
map of MSC trials by country January 2014
Jan 2014   Most scientists think of mesenchymal stromal cells (MSC, or mesenchymal stem cells) as being associated with bone marrow or adipose tissue. However, new explorations of MSC derived from umbilical cord tissue (UC-MSC) promises abundance and great therapeutic value of these cells.